Q32 Bio Inc.: stock overview

QTTBNASDAQHealthcare · Pharmaceutical Preparations

Price

$8.71

November 13, 2026Market cap $261M

DCF calculator

What Ploutos Investor adds for Q32 Bio

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 8 fiscal years, from 2018
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.

In short

Q32 Bio had revenue of $54M in the fiscal year to December 31, 2025 and net income of $32M, a net margin of 55.5%. Revenue grew by 81.9% a year on average over the last 5 years. At $8.71 the shares trade at a P/E of 8.1. It holds more cash than debt, by $286M. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$261M
29.92M shares
P/E
8.1
Revenue, fiscal year
$54M
+81.9% a year over 5 years
Net margin
55.5%
above 98% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

Fiscal years in figures

QTTB's revenue, profit, cash flow and dividend with each year-end price, from 2018 to 2022, 5 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $49M
$261M
Enterprise value 
–
P/E 
8.1
EV / EBIT 
–
EV / Revenue 
–
P/B 
0.9
FCF yield 3-year median: -69.1%
–
Earnings yield 3-year median: -191.3%
12.4%

Profitability

Operating margin 
31.5%
Net margin 
55.5%
ROIC 
31.8%
ROIC, 5-year average 
-311.0%
ROE 
34.8%

Growth

Revenue, yearly change 
–
EPS, yearly change 
–
FCF, yearly change 
–
Revenue, average a year 
+81.9%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$290M
Total debt 
$8.6M
Of which operating leases 
$5.1M
Net cash 
$286M
Net debt / EBITDA 
-16.6x
Interest cover 
–
Current ratio 
56.34

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+19.9%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Operating margin

31.5%

Above 92% of the 285 companies in its industry, and 93% of all.

Net margin

55.5%

Above 98% of the 302 companies in its industry, and 98% of all.

ROE

70.9%

Above 96% of the 267 companies in its industry, and 98% of all.

ROA

48.2%

Above 98% of the 313 companies in its industry, and 99% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
Q32 Bio Inc.
CIK
1661998
Exchange
NASDAQ
Industry (SIC)
2834 · Pharmaceutical Preparations
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
29.92M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Q32 Bio's filings show?

These are Q32 Bio's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about QTTB

Didn't find what you were looking for?

Ask us
What is QTTB's market cap?

Q32 Bio Inc.'s market cap is $261M, at a price of $8.71 on November 13, 2026 and 29.92M shares.

What is QTTB's P/E?

QTTB's P/E is 8.1, on earnings per share of $1.08 over the last 12 months.

How much revenue does QTTB have?

Q32 Bio had revenue of $54M in the fiscal year to December 31, 2025. Over the last 5 years it changed by +81.9% a year on average.

Does QTTB pay a dividend?

No. Q32 Bio paid no regular dividend over the last 12 months.

Where do the figures come from?

From Q32 Bio Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.